ZYME Stock Forecast: Zymeworks, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$26
−2.68% on the day

The 14 Wall Street analysts covering Zymeworks, Inc. hold a median 12-month price target of $42 — +58.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 83 of 100 as at 21 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$1.9B
Ticker Nerd rank
83/ 100
Median analyst target
$42
Analysts covering
14
Revenue$4.6M−90.6% y/y
Operating income−$42.1M
Net income−$45.0M
Free cash flow−$31.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.4%
1M
−2.9%
YTD
−0.7%
1Y
+9.7%
From 52W high
−16.9%
From 52W low
+19.9%
$22
$31
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Zymeworks, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
83/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
97
Growth
96
Volatility
96
Momentum
93
Quality
91
Revisions
54
Issuance
31
Accruals
10

Value (97): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Accruals (10): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ZYME stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ZYME, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$30$40$50$60Jan 26Apr 26Jul 26Oct 26ZYMEHigh $60Median $42Low $35

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says14 analysts
14
Buy
0
Hold
0
Sell
$35
Low
$42
Median
$60
High

The green dot is the last close — the median target sits +58.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 17 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
13 Nov 2026CitizensMaintainsMarket Outperform$32 → $39
11 Nov 2026CitigroupMaintainsBuy$39 → $44
10 Nov 2026HC Wainwright & Co.MaintainsBuy$55 → $56
10 Nov 2026TD CowenMaintainsBuy$34 → $39
10 Nov 2026Truist SecuritiesMaintainsBuy$35 → $36
28 Oct 2026Truist SecuritiesMaintainsBuy$34 → $35
7 Oct 2026Truist SecuritiesMaintainsBuy$32 → $34
29 Sept 2026CitigroupMaintainsBuy$38 → $39
17 Sept 2026Wolfe ResearchInitiatesOutperform—
3 Sept 2026JP MorganMaintainsOverweight$31 → $33
26 Aug 2026CitigroupMaintainsBuy$37 → $38
26 Aug 2026CitizensReiteratesMarket Outperform$32
26 Aug 2026HC Wainwright & Co.MaintainsBuy$51 → $55
10 Aug 2026B. Riley SecuritiesReiteratesBuy$40 → $44
7 Aug 2026Truist SecuritiesMaintainsBuy$31 → $32
7 Aug 2026Wells FargoMaintainsOverweight$37 → $40
5 Aug 2026HC Wainwright & Co.MaintainsBuy$46 → $51
7 July 2026Truist SecuritiesMaintainsBuy$28 → $31
30 June 2026Wells FargoMaintainsOverweight$34 → $37
3 June 2026HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ZYME.

Market Radar

This page is one stock. Monday covers all of them.

ZYME appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ZYME vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Zymeworks, Inc. returned +9.7% against +6.9% for the S&P 500, dividends included.

ZYME vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130Jan 26Apr 26Jul 26Oct 26ZYMES&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ZYME analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
+34.2%
Analysts raising
3
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
51.5×

Cheaper than 16% of US stocks

Price / sales
7.1×

Cheaper than 15% of US stocks

Price / book
7.5×

Cheaper than 11% of US stocks

EV / EBITDA
27.7×

Cheaper than 13% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
22.6%

Higher than 82% of US stocks

Net margin
—
Returns & dividend
Return on equity
15.0%

Higher than 74% of US stocks

Return on assets
4.8%

Higher than 74% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Zymeworks, Inc. has a market value of $1.9B and an enterprise value of $1.8B.

  • Revenue in the twelve months to 30 June 2026: $37.1M. The latest quarter shrank 90.6% year on year.

  • Net income over the same four quarters: −$150.0M, a −404.0% net margin.

  • Diluted earnings per share, trailing twelve months: −$2.02.

  • Free cash flow in the twelve months to 30 June 2026: −$120.7M.

  • Zymeworks, Inc. spent $169.8M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 72.0M.

  • Trailing P/E: 51.5×; forward P/E: 57.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Zymeworks, Inc. employs 279 people — $133K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

ZYME and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ZYMEZymeworks, Inc.$1.9B83
HRMYHarmony Biosciences Holdings, Inc.$1.9B72
IMNMImmunome, Inc.$1.9B21
TRVITrevi Therapeutics, Inc.$1.9B43
SEPNSepterna, Inc.$1.8B54
COAGHemab Therapeutics Holdings, Inc.$1.8B2
LYCALycia Therapeutics, Inc.$1.9B1

Take a look at ZYME’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Zymeworks, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about ZYME

What is the ZYME stock price forecast for 2026-2027?

The 14 Wall Street analysts covering Zymeworks, Inc. have a median 12-month price target of $42, with estimates ranging from $35 to $60. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ZYME stock a buy right now?

Of the 14 analysts covering Zymeworks, Inc., 14 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Zymeworks, Inc. 83 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ZYME?

As at 21 Nov 2026, Zymeworks, Inc. ranks 83 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (97 of 100).

Will ZYME stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +58.8% from the last close, and Ticker Nerd's factor model ranks Zymeworks, Inc. 83 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ZYME stock forecast for 2030?

No analyst covering Zymeworks, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ZYME are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $35 to $60 over the next 12 months.

How has ZYME stock performed over the past year?

Zymeworks, Inc. returned +9.7% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Zymeworks, Inc. do?

Zymeworks Inc. is a biotechnology company focused on discovering, developing, and commercializing multifunctional biotherapeutics for cancer and other serious diseases. The company operates across therapeutic areas including oncology, inflammation, and autoimmune disease, using proprietary antibody-based platforms to design differentiated drug candidates.

Company

About Zymeworks, Inc.

Zymeworks Inc. is a biotechnology company focused on discovering, developing, and commercializing multifunctional biotherapeutics for cancer and other serious diseases. The company operates across therapeutic areas including oncology, inflammation, and autoimmune disease, using proprietary antibody-based platforms to design differentiated drug candidates. Its current portfolio includes clinical-stage programs and licensed healthcare assets, supported by integrated research, development, and commercialization capabilities. Zymeworks also works with antibody-drug conjugate technologies and other advanced biologic platforms aimed at improving precision and therapeutic performance across difficult-to-treat conditions. With operations centered on modern drug innovation, Zymeworks Inc. plays a role in advancing next-generation treatments within the global biopharmaceutical market.

CEO Mr. Kenneth H. Galbraith C.A. · 279 employees · United States · https://www.zymeworks.com